Literature DB >> 22627000

Assessing the optimal time point for the measurement of extrastriatal serotonin transporter binding with 123I-FP-CIT SPECT in healthy, male subjects.

Karin E Koopman1, Susanne E la Fleur, Eric Fliers, Mireille J Serlie, Jan Booij.   

Abstract

UNLABELLED: (123)I-N-ω-fluoropropyl-2β-carboxymethoxy-3β-(4-iodophenyl)nortropane ((123)I-FP-CIT) is commonly used to assess the dopamine transporter in the striatum. However, recent studies suggest that this tracer may be used also to assess binding to monoamine transporters in the midbrain or diencephalon, which may reflect predominantly serotonin transporter (SERT) binding. However, it is still unclear at what time point after injection SPECT should be performed for optimal assessment of SERT with(123)I-FP-CIT. Therefore, we examined the time course of extrastriatal (123)I-FP-CIT binding.
METHODS: Nineteen healthy, male subjects were included, and SPECT images were acquired up to 3 h after (123)I-FP-CIT injection. Region-of-interest analysis was performed, and specific-to-nonspecific binding ratios were calculated.
RESULTS: Specific-to-nonspecific (123)I-FP-CIT binding ratios in the midbrain and diencephalon were significantly higher 2 h after injection than 1 h after injection and remained stable between 2 and 3 h after injection.
CONCLUSION: The optimal time frame for assessing (123)I-FP-CIT binding to extrastriatal SERT is between 2 and 3 h after injection of the tracer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22627000     DOI: 10.2967/jnumed.111.102277

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  14 in total

1.  Comments on Eusebio et al.: Voxel-based analysis of whole-brain effects of age and gender on dopamine transporter SPECT imaging in healthy subjects.

Authors:  Jan Booij; Elsmarieke van de Giessen; Swen Hesse; Osama Sabri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-10-24       Impact factor: 9.236

2.  Extrastriatal dopaminergic and serotonergic pathways in Parkinson's disease and in dementia with Lewy bodies: a 123I-FP-CIT SPECT study.

Authors:  Andrea Pilotto; Francesca Schiano di Cola; Enrico Premi; Roberto Grasso; Rosanna Turrone; Stefano Gipponi; Andrea Scalvini; Elisabetta Cottini; Barbara Paghera; Valentina Garibotto; Maria Cristina Rizzetti; Laura Bonanni; Barbara Borroni; Silvia Morbelli; Flavio Nobili; Ugo Paolo Guerra; Daniela Perani; Alessandro Padovani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-05-16       Impact factor: 9.236

3.  Diet-induced changes in the Lean Brain: Hypercaloric high-fat-high-sugar snacking decreases serotonin transporters in the human hypothalamic region.

Authors:  Karin Eva Koopman; Jan Booij; Eric Fliers; Mireille Johanna Serlie; Susanne Eva la Fleur
Journal:  Mol Metab       Date:  2013-08-07       Impact factor: 7.422

4.  Extrastriatal binding of [¹²³I]FP-CIT in the thalamus and pons: gender and age dependencies assessed in a European multicentre database of healthy controls.

Authors:  Walter Koch; Marcus Unterrainer; Guoming Xiong; Peter Bartenstein; Markus Diemling; Andrea Varrone; John C Dickson; Livia Tossici-Bolt; Terez Sera; Susanne Asenbaum; Jan Booij; Ozlem L Kapucu; Andreas Kluge; Morten Ziebell; Jacques Darcourt; Flavio Nobili; Marco Pagani; Swen Hesse; Thierry Vander Borght; Koen Van Laere; Klaus Tatsch; Christian la Fougère
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-05-08       Impact factor: 9.236

5.  The relationship between the dopaminergic system and depressive symptoms in cervical dystonia.

Authors:  E Zoons; M A J Tijssen; Y E M Dreissen; J D Speelman; M Smit; J Booij
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-03-17       Impact factor: 9.236

6.  The Effect of Escitalopram on Central Serotonergic and Dopaminergic Systems in Patients with Cervical Dystonia, and Its Relationship with Clinical Treatment Effects: A Double-Blind Placebo-Controlled Trial.

Authors:  Evelien Zoons; Marina A J Tijssen; Yasmine E M Dreissen; Marenka Smit; Jan Booij
Journal:  Biomolecules       Date:  2020-06-08

7.  Imaging of serotonin transporters with [123I]FP-CIT SPECT in the human hypothalamus.

Authors:  Anke J Borgers; Anneke Alkemade; Elsmarieke M Van de Giessen; Madeleine L Drent; Jan Booij; Peter H Bisschop; Eric Fliers
Journal:  EJNMMI Res       Date:  2013-04-25       Impact factor: 3.138

8.  SERT-to-DAT ratios in early Parkinson's disease do not correlate with the development of dyskinesias.

Authors:  Sven R Suwijn; Henk W Berendse; Constant Vm Verschuur; Ania Winogrodzka; Rob Ma de Bie; Jan Booij
Journal:  EJNMMI Res       Date:  2013-06-05       Impact factor: 3.138

9.  Lower serotonin transporter binding in patients with cervical dystonia is associated with psychiatric symptoms.

Authors:  E Zoons; J Booij; J D Speelman; Y E M Dreissen; M Smit; M A J Tijssen
Journal:  EJNMMI Res       Date:  2017-10-25       Impact factor: 3.138

10.  Lower 123I-FP-CIT binding to the striatal dopamine transporter, but not to the extrastriatal serotonin transporter, in Parkinson's disease compared with dementia with Lewy bodies.

Authors:  Merijn Joling; Chris Vriend; Jessica J van der Zande; Afina W Lemstra; Odile A van den Heuvel; Jan Booij; Henk W Berendse
Journal:  Neuroimage Clin       Date:  2018-04-06       Impact factor: 4.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.